Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ADAG
ADAG logo

ADAG Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Adagene Inc (ADAG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.410
1 Day change
12.50%
52 Week Range
4.580
Analysis Updated At
2026/03/26
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Adagene Inc (ADAG) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the technical indicators show a bullish trend, the lack of significant news, trading trends, financial data, and proprietary trading signals suggests limited immediate upside potential. Additionally, the stock's projected short-term performance is modest, making it less appealing for a long-term investment strategy.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 66.027, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 4.353 and 4.603, while support levels are at 3.543 and 3.293. Overall, the technical indicators suggest a positive trend.

Positive Catalysts

  • Bullish technical indicators such as MACD expansion and moving averages alignment.

Neutral/Negative Catalysts

  • No recent news, no significant trading trends from hedge funds or insiders, no congress trading data, and no proprietary trading signals.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast ADAG stock price to rise
2 Analyst Rating
Wall Street analysts forecast ADAG stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.610
sliders
Low
8
Averages
8.5
High
9
Current: 4.610
sliders
Low
8
Averages
8.5
High
9
Guggenheim
initiated
$9
AI Analysis
2025-11-24
Reason
Guggenheim
Price Target
$9
AI Analysis
2025-11-24
initiated
Reason
As previously reported, Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target. The company's lead product candidate muzastotug is currently in Phase 2 for patients with late-line microsatellite stable colorectal cancer without liver metastases, notes the analyst. The company has reported "compelling" Phase 1 data for muzastotug plus pembrolizumab that exceed current standard of care benchmarks in third-line and later CRC, according to the analyst, who calls this "an area of significant unmet need."
Guggenheim
initiated
$9
2025-11-24
Reason
Guggenheim
Price Target
$9
2025-11-24
initiated
Reason
Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ADAG
Unlock Now

People Also Watch